AF
FTH

Amalgamated Financial’s Faeth Therapeutics FTH Stock Holding History

Amalgamated Financial’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$6K Buy
+126
New +$10K ﹤0.01% 2955

Other funds holding FTH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Amalgamated Financial's FTH Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Faeth Therapeutics (FTH) in Q1 2022: 126 shares worth $6K. The stake represents ﹤0.01% of the portfolio and ranks #2955 among its holdings.

42 funds tracked by Wall St. Rank hold FTH as of Q1 2022.

  • Amalgamated Financial held 126 shares of Faeth Therapeutics worth $6K as of Q1 2022.
  • Faeth Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Faeth Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2955 holding.
  • 42 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.